Its polymorphic variant RAD51-G135C has been suggested to be correlated with the onset of therapy-related AML by several case-control studies, even if two meta-analyses seem to dismiss the role of this polymorphism in de novo AML onset [51,52,53,54]. This evidence concerns the gene RAD51 and acute myeloid leukemia.